XEN-D0501
XEN-D0501 is an experimental transient receptor potential vanilloid 1 (TRPV1) antagonist.[1][2][3] It was acquired by Pila Pharma from Ario Pharma in 2016.[4]
References[edit]
- ^ Round, Patrick; Priestley, Anthony; Robinson, Jan (December 2011). "An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects". British Journal of Clinical Pharmacology. 72 (6): 921–931. doi:10.1111/j.1365-2125.2011.04040.x. PMC 3244639. PMID 21676011.
- ^ Andersson, Karl-Erik (2 September 2019). "Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels?". Expert Opinion on Investigational Drugs. 28 (9): 749–755. doi:10.1080/13543784.2019.1654994. PMID 31399015.
- ^ Belvisi, Maria G.; Birrell, Mark A.; Wortley, Michael A.; Maher, Sarah A.; Satia, Imran; Badri, Huda; Holt, Kimberley; Round, Patrick; McGarvey, Lorcan; Ford, John; Smith, Jaclyn A. (15 November 2017). "XEN-D0501, a Novel Transient Receptor Potential Vanilloid 1 Antagonist, Does Not Reduce Cough in Patients with Refractory Cough". American Journal of Respiratory and Critical Care Medicine. 196 (10): 1255–1263. doi:10.1164/rccm.201704-0769OC. hdl:10044/1/52994. PMID 28650204. S2CID 196479866.
- ^ Otmani, Malin (5 April 2016). "Pila Pharma acquires Ario Pharma's TRPV1 assets". Nordic Life Science – the leading Nordic life science news service. Retrieved 1 December 2023.